Huntington's disease (HD) is an inherited neurodegenerative disorder caused by a CAG repeat expansion within exon 1 of the huntingtin (HTT) gene. HTT mRNA contains 67 exons and does not always splice between exon 1 and exon 2 leading to the production of a small polyadenylated HTTexon1 transcript, and the full-length HTT mRNA has three 3′UTR isoforms. We have developed a QuantiGene multiplex panel for the simultaneous detection of all of these mouse Htt transcripts directly from tissue lysates and demonstrate that this can replace the more work-intensive Taqman qPCR assays. We have applied this to the analysis of brain regions from the zQ175 HD mouse model and wild type littermates at two months of age. We show that the incomplete splicing of Htt occurs throughout the brain and confirm that this originates from the mutant and not endogenous Htt allele. Given that HTTexon1 encodes the highly pathogenic exon 1 HTT protein, it is essential that the levels of all Htt transcripts can be monitored when evaluating HTT lowering approaches. Our QuantiGene panel will allow the rapid comparative assessment of all Htt transcripts in cell lysates and mouse tissues without the need to first extract RnA.
Huntington's disease (HD) is an autosomal dominant disorder that is characterised by movement disorders, as well as psychiatric and cognitive disturbances 1 . It is caused by the expansion of a CAG repeat in exon 1 of the huntingtin gene (HTT), which is translated to a huntingtin protein (HTT) with an abnormally long polyglutamine tract 2 . CAG repeats of 40 or more are fully penetrant, alleles of 36 to 39 result in an increased likelihood that HD will occur within a normal life span and individuals with 35 or less remain unaffected 3 . There is a negative correlation between the age of onset of motor symptoms and the length of the CAG repeat as measured in blood, with expansions of 70 and above resulting in onset before 20 years of age. Somatic expansion of the CAG repeat in neurons can lead to CAG repeat lengths in brain that are considerably longer than those present in blood 4, 5 .
The mammalian HTT gene is approximately 180 kb in length and contains 67 exons. Two mature transcripts of approximately 10.3 and 13.7 kb were initially described that differed in the length of their 3′UTRs 6 . The recent identification of an additional polyadenylation (poly(A)) site in the 3'UTR results in a HTT transcript of approximately 12.5 kb, with the result that we now know that three full-length human HTT transcripts are produced 7 . In addition, we have previously shown that exon 1 of HTT does not always splice to exon 2, resulting in two small polyadenylated mRNAs (Httexon1) 8 . In mouse, these extend to cryptic poly(A) sites located at 680 and 1,145 bp into intron 1 8, 9 , and in human, to cryptic poly(A) sites extending to 2,710 and 7,327 bp into intron 1 8, 10 . The extent to which this incomplete splicing event occurs increases with increasing CAG repeat length 8 and the Httexon1 transcripts are translated to generate the highly pathogenic exon 1 HTT protein 8 . These alternative mRNA processing events mean that at least five transcripts are produced from the human HTT and mouse Htt genes, which are translated to produce either full length HTT or the exon 1 HTT protein.
Strategies to lower the levels of HTT mRNA are a major focus for HD therapeutics and are at various stages of development. These were discussed in a recent review 11 and include antisense oligonucleotides (ASOs), interfering RNAs (RNAi) and small molecule splicing modulators for targeting RNA, and zinc-finger transcription factors and CRISPR/Cas9 for targeting DNA. ASOs targeting HTT mRNA are the most advanced, and their intrathecal delivery has been shown to be tolerated in a phase II clinical trial and to result in the reduction of mutant HTT protein in cerebrospinal fluid (CSF) 12 . In some cases, these strategies target all HTT transcripts, but in others, they target the full length transcripts whilst leaving the Httexon1 transcripts intact. As the exon 1 HTT protein is highly pathogenic 13, 14 , and the relative contribution of the mutant forms of the full length HTT and the exon 1 HTT proteins to disease pathogenesis is unknown, it is important that we can measure the extent to which the levels of all HTT transcripts are affected by these various strategies.
QuantiGene assays are based on branched DNA (bDNA) technology [15] [16] [17] , have a workflow that is easy and fast to perform in a multiplex 96-well plate format, are devoid of additional steps after homogenisation of the tissues of interest and are sensitive enough to detect low abundance transcripts. QuantiGene singleplex assays have been used in the past for quantifying huntingtin mRNA expression [18] [19] [20] . Therefore, we set out to establish a QuantiGene multiplex assay to provide a method for measuring all of the mouse Htt transcripts of interest concomitantly and validated this through the direct comparison with quantitative real-time PCR (qPCR). We applied this assay to measure Htt transcripts in the zQ175 knock-in model of HD 21, 22 that is used extensively for therapeutic target validation. We extended previous work 8 to show that the Httexon1 transcript is present throughout the brain in this model and provide further evidence to confirm that it originates from the mutant Htt allele. In summary, the QuantiGene multiplex assay provides a rapid and reliable means of measuring the levels of mouse Htt transcripts directly in tissue homogenates.
Results
QuantiGene Htt multiplex assay custom design. In collaboration with Thermofisher, we set out to design a multiplex QuantiGene panel to detect the incompletely spliced (Httexon1) and full-length Htt (Htt-FL) transcripts ( Fig. 1 ). This contained probes to intron 1 before the first cryptic poly(A) site at 680 bp (I 1 -pA 1 ), to intron 1 sequences after this and before the second cryptic poly(A) site at 1,145 bp (I 1 -pA 2 ), to sequences at the 3′ end of intron 1 (I 1 -3′), within intron 3 (I 3 ) and to exons 50-53 for the fully-spliced coding sequence (E50-53). The two cryptic poly(A) sites are 465 bp apart, raising the possibility that the amplification trees corresponding to these two sequences might interfere due to their close proximity. To address this, we designed the 9-plex and 10-plex QuantiGene panels outlined in Table 1 .
The I 1 -pA 1 probe set identifies the Httexon1 transcripts that terminate at both the first and the second cryptic poly(A) signals. The I 1 -pA 2 probe set recognises only the Httexon1 transcript that terminates at the second poly(A) signal, while the I 1 -3′ probe set would identify incompletely spliced intron 1 sequences that have not terminated at cryptic poly(A) signals. The I 3 probe set serves to control for any contaminating Htt pre-mRNA. The housekeeping reference genes chosen for the panels have been identified previously for their robustness and stability when used in brain tissues from HD mouse models 23 .
Establishment and optimisation of QuantiGene
Htt multiplex assays. To examine the linearity of the probe set signals for each brain region, we used a pool of equimolar lysate from wild type (WT) and zQ175 heterozygous animals (n = 4/genotype). The two pools were then subjected to 2-fold serial dilutions and QuantiGene analysis using our 9-plex and 10-plex panels.
The lowest mean fluorescence intensity (MFI) signal for the striatum corresponded to the control I 3 probe set, while the highest corresponded to that for the reference gene Ubc (Fig. 2c,h and Supplementary Fig. S1 ). The MFI signal for the I 1 -3′ probe set was comparable to the assay background (I 3 ) even at the highest concentration used ( Fig. 2b ,g,c,h). The linear regression of the MFI signals for the reference genes Ubc and Eif4a2 in the striatum, for both the 9-plex and 10-plex QuantiGene panels, showed that the signal was saturated for the undiluted material ( Supplementary Fig. S1 ). Thus, the undiluted material was excluded from the linear range for all probe sets in all other brain regions ( Supplementary Figs S2-S5 ). Based on the linearity of the probe set signals and the coefficient Figure 1 . Schematic representation of the location of the probe sets for the multiplex Htt QuantiGene assays. Custom probe sets were designed against Htt mRNA sequence to enable the measurement of all major Htt transcripts. The 9-plex assay contained probe sets to intron 1 sequences before the first cryptic polyA site at 680 bp to detect the Httexon1 transcripts, to the 3′ end of intron 1 and to intron 3 as controls for unprocessed mRNA, and to exons 50-53 for all Htt-FL transcripts. The 10-plex assay included a probe set to sequences between the first and second cryptic polyA sites, between 680 and 1145 bp. The 14-plex assay also included probe sets to each of the three 3′UTRs of the full-length transcript.
of variance (% CV) we recommend a dilution range of the starting material of 1:3-1:4 and never more than 1:5 for all brain regions (Supplementary Table 1 ). Close evaluation of the Ubc signal suggested that saturation had been reached for all brain regions, even at the lowest dilution range, and therefore, Ubc was excluded from all further analyses.
Importantly, the striatal MFI signal for the I 1 -pA 1 probe set (for both plex panels) ( Fig. 2a ,e) and for the I 1 -pA 2 probe set (for the 10-plex panel) ( Fig. 2f ) suggested that the genotypes behaved differently for these early intron 1 sequences. There was considerably more signal in the zQ175 pool than in the WT, as indicated by the difference in the linear regression slopes. The MFI signal for the I 1 -pA 1 probe set showed a similar linear range of detection in both the 9-and 10-plex panels ( Fig. 2a,e ). The signal for the I 1 -pA 2 probe set on the 10-plex panel ( Fig. 2f ) was significantly greater for the zQ175 heterozygotes than for WT. The MFI signal for the I 1 -3′ probe sets was comparable to I 3 for both WT and zQ175 lysates ( Fig. 2b ,g,c,h for striatum and Supplementary Figs S2-S5 for other brain regions). The linear ranges for the probe sets for Htt-FL are shown in Fig. 2d ,i, and Supplementary Figs S2-S5. Taken together, these data suggest that the 10-plex QuantiGene panel can be used to detect all Htt transcripts, without compromising the fluorescent signal due to the close proximity between the I 1 -pA 1 and I 1 -pA 2 probe sets. At the dilutions recommended, the housekeeping genes gave comparable signals for the two genotypes (Supplementary Figs S1-S5).
Validation of the QuantiGene Htt 10-plex assay. We set out to validate our 10-plex QuantiGene panel by comparing the expression levels of the Htt transcripts as measured by this approach with that determined by real time quantitative PCR (qPCR). The levels of Htt transcripts were measured in brain regions from zQ175 heterozygotes and WT littermates at 2 months of age (n = 4/genotype). The locations of the qPCR assays corresponded to the position of the QuantiGene probe sets, except that we did not include a qPCR assay for intron 3 ( Supplementary Table S2 ).
The level of the Httexon1 transcript was shown to be abundant in the striatum, cortex, hippocampus, cerebellum and brain stem of zQ175 mice as compared to WT by both approaches (Fig. 3 ). Both assays confirm that the level of 3′ intron 1 sequences are at background levels ( Fig. 3 ). This is in keeping with our previous RNAseq data indicating that transcription terminates at the second cryptic poly(A) site 8 . In the zQ175 samples, the signal from the QuantiGene I 1 -pA 2 probe set is higher than that for I 1 -pA 1 (Fig. 3a-d ). As it is not possible for the level of the intron 1 sequences between poly(A) 1 and poly(A) 2 to be greater than that before poly(A) 1 , this may reflect differences in hybridisation efficiencies. This most likely accounts for the higher I 1 -pA 2 signal in WT mice, which we consider to be background noise; the qPCR data suggest that any level of incomplete splicing that occurs in WT mice is below the level of detection (the readings for the I 1 -pA 1 and I 1 -pA 2 assays are not greater than for I 1 -3′).
The Htt-FL transcript was also analysed in all five brain regions. In the striatum, the level of Htt-FL was reduced to approximately 70% -80% of WT levels in the zQ175 mice as measured by both assays (Fig. 3f,p) . For all of the other brain regions, the situation was less clear cut, although in all cases the mean level of Htt-FL expression was lower in the zQ175 than WT mice (Fig. 3 ). The qPCR assay gave tighter data for the cortex in which the reduction of Htt-FL could be detected (Fig. 3q ). In comparison, the QuantiGene data was more variable, and so we would recommend that more than 4 samples per genotype should be analysed.
Design and application of a QuantiGene Htt 14-plex assay. We next extended our 10-plex assay to include probes against each of the three 3′UTR isoforms of Htt (short-, mid-and long-3′UTR) 7 and an additional housekeeping reference gene, Ppib 18,20 ( Fig. 1 and Supplementary Table S3 ). To ensure that the new 14-plex panel could detect all Htt transcripts and Ppib, we analysed the same zQ175 and WT lysates as had been used for the 10-plex panel (n = 4/genotype). The Httexon1 transcript levels in zQ175 mice were comparable to those detected with the 10-plex assay ( Supplementary Fig. S6 and Fig. 3 ), except in brain stem, where they showed less variability, and consequently, the difference in the levels between zQ175 and WT samples was statistically significant. The E50-53 probe set, as well as each of the 3′UTR assays, showed a statistically significant reduction in Htt-FL levels in zQ175 as compared to WT samples for the striatum, cortex and hippocampus ( Supplementary Fig. 6 ).
To further assess the application of the 14-plex QuantiGene panel, and to test the consistency of our data, we repeated our analysis of Htt transcripts in a different cohort of mice (n = 8/genotype) ( Fig. 4) . We could detect a statistically significant increase in the Httexon1 transcript in the zQ175 mice as compared to WT in all five brain Table 1 . Design of the 9-plex and 10-plex QuantiGene assays for the detection of Htt transcripts. GOI = gene of interest, HK = housekeeping reference gene. The levels of Htt-FL as measured by both approaches were comparable. Data were obtained from n = 4/genotype with two technical replicates for QuantiGene and three for qPCRs. Statistical analysis was by multiple t-test with Benjamini-Hochberg with an alpha of 0.05; *p < 0.05, **p < 0.01, ***p < 0.001. Tissue lysate dilutions were 1:3 for striatum and brain stem, 1:4 for cortex and cerebellum and 1:5 for hippocampus.
regions tested ( Fig. 4a-e ). This correlated with a statistically significant reduction in Htt-FL levels as measured by all four of the Htt-FL assays for striatum (~23%), cortex (~22%) and hippocampus (~22%) ( Fig. 4f-j) .
Overall, we conclude that our 14-plex QuantiGene assay can reliably compare differences in the levels of the Httexon1 and Htt-FL transcripts between the zQ175 mouse model of HD and WT littermates. the level of the Httexon1 transcript in zQ175 tissues corresponds to a reduction in mutant and not endogenous Htt-FL. We found that the level of the Htt-FL transcript was consistently decreased in zQ175 striatum, cortex and hippocampus ( Fig. 4) and Supplementary Fig. S6 ). In order to determine whether this reflected a decrease in the endogenous transcript, the mutant transcript, or both, we employed an allele-specific qPCR assay (Fig. 5 ). We found that the level of endogenous Htt-FL was 50% of WT levels in all five brain regions for zQ175 mice. Therefore, any reductions in the level of Htt-FL must correspond to decreases in the mutant Htt-FL transcript. This is consistent with our failure to detect incomplete splicing of the endogenous Htt transcript in WT mice (Figs 2 and 4 and Sathasivam et al. 2013 ).
Discussion
In this study, we have assessed the expression of all known major Htt transcripts in the brains of the zQ175 mouse model of HD. We developed a multiplex QuantiGene assay based on the rapid, robust and high-throughput bDNA technology 17 for this purpose and demonstrated that this can be used to replace qPCR for studies comparing Htt transcripts between samples. We applied the QuantiGene assay to the comparison of Htt transcripts in various brain regions between zQ175 and WT littermates at 2 months of age, and showed that incomplete slicing occurs throughout the brain for zQ175, but not WT, animals. Finally, we provide evidence to indicate that the Httexon1 transcript originates from the incomplete splicing of the mutant Htt allele.
We have developed and optimised a 14-plex QuantiGene assay to enable us to detect all major Htt transcripts directly from tissue lysates, obviating the need to prepare RNA and replacing the more labour-intensive qPCR. This assay includes probe sets targeting sequences extending to the first and second cryptic poly(A) sites in intron 1, to detect incomplete splicing; to the 3′ end of intron 1 and to intron 3, to give an indication of pre-mRNA background; to exons 50-53 and each of the 3′UTRs (short, mid and long) to detect Htt-FL and shifts in 3′UTR usage; as well as six housekeeping genes. We have applied this to the analysis of Htt transcripts in five brain regions from the zQ175 knock-in mouse model of HD and WT littermates. For each brain region, we calculated the lysate dilution required to ensure that mean fluorescence intensity (MFI) signals were in the linear range and recommend using dilutions at the lower end of the range detailed in Supplementary Table S1 . We caution against using lysates that have been subjected to multiple freeze-thaw cycles, and a recent study suggested that the use of 'RNAlater' , when preparing QuantiGene lysates, might better preserve long mRNAs, such as Htt-FL, which are more prone to degradation 18 .
QuantiGene analysis of Htt transcripts in brain regions of 2 month old zQ175 mice (Fig. 4) showed that intronic sequences 5′ to the cryptic poly(A) sites (I 1 -pA 1 and I 1 -pA 2 ) were present in zQ175 cortex, striatum, hippocampus, cerebellum and brain stem at higher levels than in WT, indicating that incomplete splicing of Htt occurs in all of these brain regions. The levels of intronic sequences at the 3′ end of intron 1 (I 1 -3′) were comparable to intron 3 (I 3 ), indicative of pre-mRNA background. This is consistent with our previous RNAseq data showing that the incompletely spliced intron 1 sequence reads terminate at the second cryptic poly(A) site 8 . In all cases, the level of intron 1 sequences between the two poly(A) sites (I 1 -pA 2 ) was higher than that before the first poly(A) site (I 1 -pA 1 ). As it is not possible that the mRNA level between the poly(A) sites is higher than before the first poly(A), this must be a reflection of the differential efficiency of probe binding. The 14-plex analysis of WT tissues (I 1 -pA 1 and I 1 -pA 2 ) suggested that the incomplete splicing of Htt might be occurring in WT mice to a lesser extent. However, examination of the qPCR data ( Fig. 3) , for which the I 1 -pA 1 , I 1 -pA 2 and I 1 -3′ assays give comparable data, indicates that this is unlikely, but arising instead from the differential efficiency of probe-set binding. Therefore, the 14-plex QuantiGene assay provides a valuable tool for comparative analyses between samples but, as used here, is not quantitative.
The level of Htt-FL transcript, as detected by all four probe sets (E50-53, s-3′UTR, m-3′UTR and l-3′UTR) is lower in zQ175 striatum, cortex and hippocampus than in WT mice. We employed an allele specific qPCR assay that selectively detects endogenous Htt in this knock-in model, and found that the level of the endogenous Htt-FL was not decreased in the heterozygous zQ175 mice. That the reduction in Htt-FL corresponds to a decrease in the mutant transcript, and that this is a consequence of incomplete splicing between exon 1 and exon 2 is consistent with our observation that incomplete splicing of endogenous Htt does not occur in WT mice and our previous RNAseq data 8 .
We have previously shown that the incomplete splicing of exon 1 to exon 2 of Htt results in the Httexon1 polyadenylated mRNA that is translated to produce the highly pathogenic exon 1 HTT protein [8] [9] [10] . The extent of incomplete splicing increases with increasing CAG repeat length, therefore, somatic CAG expansion would be expected to result in the increased production of the exon 1 HTT protein. Genome-wide association studies have identified a number of DNA repair genes as genetic modifiers of HD that have been shown to modulate somatic expansion levels [24] [25] [26] . Therefore, incomplete splicing produces a direct link between the genetic modifiers for HD and the production of a pathogenic fragment of HTT. As Htt lowering approaches are evaluated in mouse models, it is essential that their effect on the level of Httexon1 as well as Htt-FL transcripts can be assessed. Our QuantiGene assay provides a rapid method for screening Htt lowering agents targeting mouse Htt in cell culture and mouse models of HD.
Methods
Animal colony maintenance and breeding. All . Expression analysis of Htt transcripts in five brain regions using the custom-made 14-plex QuantiGene assay. The expression of intronic Htt transcripts in 2 month old mice are presented relative to that for housekeeping genes. (a-e) The Httexon1 transcript is present in all zQ175 brain regions. (f-j) The level of the Htt-FL transcript is significantly decreased in the striatum, cortex and hippocampus as measured by the E50-53 and all 3′UTR probe sets. Data were from n = 4/genotype with two technical replicates. Statistical analysis was by multiple t-test with Benjamini-Hochberg with an alpha of 0.05, *p < 0.05, **p < 0.01, ***p < 0.001. Tissue lysate dilutions were 1:3 for striatum, hippocampus and brain stem, 1:4 for cortex and cerebellum.
www.nature.com/scientificreports www.nature.com/scientificreports/ DNA extractions, genotyping and repeat sizing. Genomic DNA isolation was performed after lysing an ear-punch in 50 mM Tris-HCl, 0.5% SDS, 100 mM EDTA pH = 8.0, with 0.1 mg/mL proteinase K at 50 °C overnight. Addition of 300 μL saturated 36% (w/v) NaCl solution was followed by thorough mixing and centrifugation at 21,000 g for 30 min. The DNA-containing supernatant was transferred to a new tube with 650 μL ice-cold 100% ethanol (EtOH) followed by mixing and centrifugation at 21,000 g for 20 min. The DNA-containing pellet was washed with 70% EtOH and centrifuged at 21,000 g for 15 min. The supernatant was discarded, the DNA pellet was left to air dry and lastly the DNA was resuspended in 60 μL 5 mM Tris-HCl, pH = 8.0. Genotyping of the zQ175 animals was performed as follows: in a total volume of 20 μL reaction, 20 ng of DNA was added to a mixture of 1x Go Taq Flexi buffer (Promega), 2.5 mM MgCl 2 , 0.2 mM dNTPs, 1 μM each primer (Forward: 5′-AGGAGCCGCTGCACCGA-3′ and Reverse: 5′-CTCTTCACAACAGTCATGTGCG-3′) and 0.05 U/ μl GoTaq 2 , and the following PCR programme was used: 98 °C for 30 s, followed by 34 cycles of 98 °C for 15 s, 64 °C for 15 s, 72 °C for 30 s, and a final elongation step at 72 °C for 5 min. The PCR products were loaded on a 2.5% agarose gel containing SYBR Safe DNA gel stain (Thermofisher), subjected to electrophoresis and visualised on a BioRad Gel Doc XR+ . The CAG repeat sizing was performed as previously described 28 using the following primers: Forward: 5′-6FAM-ATGAAGGCCTTCGAGTCCCTCAAGTCCTTC-3′ and Reverse: 5′-GGCGGCTGAGGAAGCTGAGGA-3′, except that the DNA size standard was MapMarker 1000 ROX (BioVentures Inc.) and analysis of data was performed using the GeneMapper plate manager application. The CAG repeat size for the first cohort of the zQ175 mice was 197.75 ± 1.7 (S.D.) and for the second cohort was 207.5 ± 3.02.
Tissue lysis and QuantiGene assays. All Quantigene probe sets are available from ThermoFisher and the individual accession numbers and probe set regions are summarised in Supplementary Table S3 ; the sequences for the capture extenders, label extenders and blocking probes are available from ThermoFisher on request. The catalogue number for the 14-plex set validated in this manuscript is 21917. Investigators can select probe sets from this to customise their own multiplex assays, if they did not wish to include all of the Htt probe sets or all of the six housekeeping genes.
All QuantiGene reagents were from ThermoFisher. Homogenates of brain regions were prepared by adding 300 μL of working homogenisation solution (homogenisation solution (QG0517) with 1:100 (v/v) 50 mg/ mL Proteinase K (QS0512) for each 10 mg tissue) and using syringes with needles of 23 G and 18 G. Homogenates were then centrifuged at 15,000 g for 10 min and the supernatant was transferred to a fresh tube. For linearity probe set assessment, equal volumes of homogenates of the same genotype were pooled together and a 2-fold serial dilution was conducted for each pool. Otherwise, the homogenates were diluted so readings would fit in the linear range of the fluorescent signal for all probe sets in the QuantiGene panel ( Supplementary Table S1 ). The QuantiGene assays were performed as indicated in the manufacturer's protocol with the exception that the Streptavidin R-Phycoerythrin conjugate (SAPE) binding was done at 51 °C. Plates were read using a Magpix (Luminex). Data analysis was performed by normalising the signals obtained for the genes of interest to the geometric mean of the reference gene signals (Atp5b, Eif4a2, Rpl13a, Canx and Ppib as appropriate). All Htt-FL isoforms were expressed relative to the average expression of the WT animals. Technical duplicates of each sample were included in each experiment, with a minimum of two independent experiments for each cohort of animals.
RNA isolation and cDNA synthesis. Total RNA isolation was conducted using the RNeasy mini kit (Qiagen) following the manufacturer's protocol, after homogenising the tissue in Qiazol lysis reagent (Qiagen) using syringes with needles of 23 G and 18 G. DNase I treatment was performed in-column using the RNA-free DNase kit (Qiagen) before the RNA was eluted in the appropriate amount of nuclease-free H 2 O (Sigma-Aldrich). The quality and quantity of RNA was measured using a NanoDrop 1000. Reverse transcription was performed on 0.5-1 μg of RNA using the M-MLV reverse transcriptase (RT) (Invitrogen) according to the company's protocol and using oligo-dT (18) primers (Invitrogen). A negative control was included for each brain region in which no reverse transcriptase was added (-RT). Figure 5 . The level of the endogenous Htt-FL transcript is not decreased in zQ175 tissues. Allele-specific qPCR analysis of the level of the endogenous Htt-FL transcript in five brain regions from 2 month old WT and zQ175 mice. The level of the endogenous Htt-FL transcript was present at 50% WT levels in the zQ175 samples for all five brain regions. Data were obtained from n = 4/genotype. Statistical analysis was by t-test, *p < 0.05, ***p < 0.001.
